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Cardiac magnetic resonance imaging (CMR) has long
been recognized as an accurate and reliable means of
evaluating cardiac anatomy and ventricular function.
Considerable progress has been made in the ﬁeld of
CMR, providing accurate evaluation of left ventric-
ular function parameters in coronary artery disease,
heart failure, hypertrophic cardiomyopathy, and
many other cardiac diseases [1–12]. Stress ﬁrst-pass
contrast-enhanced myocardial perfusion CMR can be
used to detect subendocardial ischemia and recent
studies have demonstrated the high diagnostic accu-
racy of stress myocardial perfusion CMR for detect-
ing signiﬁcant coronary artery disease [13–16].
Magnetic resonance angiography has been introduced
as a method that can provide visualization of all three
major coronary arteries, coronary anomalies, coro-
nary bypasses and the aorta within a single three-
dimensional acquisition [17–19]. CMR has become
the ﬁrst choice imaging modality in complex con-
genital heart disease [20–26], imaging great vessels,
and evaluation of therapy such as cardiac resynchro-
nization therapy [27–38].
Over the past years, contrast-enhanced CMR has
been used to visualize the transmural extent of
myocardial infarction with high spatial resolution
[39–45]. Infarcted myocardium appears hyperen-
hanced compared with normal myocardium when
imaged by a late enhancement MRI technique with
the use of T1-weighted sequence after injection of
gadolinium chelates. Late gadolinium-enhanced
CMR can clearly delineate subendocardial infarction
and the transmural extent of delayed enhancement
potentially predicts functional outcome after revas-
cularization in acute myocardial infarction and
chronic ischemic heart disease [46–49].
In the current issue of the International Journal of
Cardiovascular Imaging, Husser et al. [50] compared
quantitative assessment of contrast CMR with visual
analysis in patients with ST-segment elevation myo-
cardial infarction (STEMI) for predicting reduced
ejection fraction and major adverse cardiac events
such as death, re-infarction, and re-admission for
heart failure. The authors studied 192 patients who
underwent CMR at 1 week and 6 months after a
sustained STEMI. Three quantitative indices (initial
slope, maximal signal intensity and contrast delay in
ﬁrst-pass imaging) and two visual perfusion indices
(hypo-enhancement in ﬁrst-pass and microvascular
obstruction in late enhancement imaging) were
evaluated. Quantiﬁcation of infarct mass and visual
assessment of the extent of transmural necrosis was
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segment model. At 6 months, 69 patients showed
reduced ejection fraction; during follow-up of mean
655 days, 20 major adverse cardiac events occurred.
Quantiﬁcation of the perfusion images was very time-
consuming and proved not superior to visual perfu-
sion analysis to predict reduced ejection fraction and/
or major adverse cardiac events. Similarly, quantiﬁ-
cation of infarct size was not superior to visual
assessment of the extent of transmural necrosis. In
multivariate analysis, only visual assessment of
extent of transmural necrosis predicted reduced
ejection fraction and major adverse cardiac events.
The authors concluded that visual analysis of CMR in
patients with STEMI is not time-consuming and
predicts reduced ejection fraction and major adverse
cardiac events comparable to quantitative analysis.
The extent of transmural necrosis turned out to be the
strongest parameter. The present study is the ﬁrst to
investigate whether a complete quantitative analysis
of a post-infarct-CMR study would be more accurate
than a complete visual analysis of microvascular
perfusion and myocardial necrosis to predict late
ejection fraction and major adverse cardiac events in
a large group of patients with STEMI. The data
conﬁrm previous ﬁndings from the same group
showing that neither qualitative nor quantitative
myocardial perfusion nor time-consuming quantiﬁca-
tion of infarct mass provides incremental predictive
value over visual assessment of transmural necrosis
[51–53].
Despite these interesting ﬁndings, it should be
realized that quantiﬁcation of perfusion and infarct
size offers the potential advantages of being less
operator-dependent, more objective, and more accu-
rate. At present, CMR offers several acquisition
techniques for precise and highly reproducible
assessment of global and regional ventricular func-
tion, ﬂow, and perfusion at rest and under pharma-
cological or physical stress conditions [54–56].
Moreover, CMR allows quantiﬁcation of blood ﬂow
over the valves, and automatic vessel wall contour
detection and quantiﬁcation of wall thickness of in-
vivo MR images of the human aorta [57–59]. Recent
advances in hardware and software have resulted in
strong improvement of image quality and in a
signiﬁcant decrease in the required imaging time for
each of these acquisitions. However, quantitative
image analysis often still relies on manual tracing of
contours in the images, being indeed time-consuming
thereby limiting the clinical applicability of CMR for
routine analysis. Methods for automated and robust
assessment of the parameters of cardiac function,
blood ﬂow and morphology, are still being developed
to overcome the limitations associated with manual
image processing [60]. Until these issues are fully
solved, the present study clearly indicates that, for
prediction of late cardiac events in patients with
STEMI, a comprehensive visual approach may suf-
ﬁce in routine clinical practice.
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